More and more Oracle Database licensees, including those using 19c, switching to Rimini Support™ and Rimini Protect™ for hyper-responsive, mission-critical database support 24/7/365, immediate 50% cost savings, avoidance of unnecessary and costly upgrades, and innovative database security solutions

(BUSINESS WIRE)--Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, products and services, the leading third-party support provider for Oracle and SAP software, and a Salesforce and AWS partner, today advised licensees running pre-19c releases of Oracle Database who no longer receive Oracle Premier Support, that they can continue using their current Oracle Database release for up to an additional 15 years without required upgrades by switching to premium Rimini Support™. Clients can also save 50% on support fees compared to Oracle Support and leverage Rimini Protect™ security solutions to signific ... Read more »

INGELHEIM, Germany & INDIANAPOLIS, Ind. - Friday, 23. June 2023

• The positive CHMP opinion is based on the landmark EMPA-KIDNEY trial, the largest and broadest dedicated SGLT2 inhibitor trial in chronic kidney disease (CKD) to date1,2,3
• When approved, Jardiance® (empagliflozin) could advance the standard of care for more than 47 million people in the EU living with CKD and other interconnected cardio-renal-metabolic conditions4

(BUSINESS WIRE) -- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending Jardiance® (empagliflozin) for the treatment of adults with chronic kidney disease (CKD), Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today.1 Empagliflozin is currently indicated for the treatment of heart failure and type 2 diabetes in adults.5 When approved, empagliflozin’s indications ... Read more »